An anti-IL-18 recombinant human antibody (tadekinig alfa) is considered as an option for patients with NLRC4 mutations or XIAP deficiency who have high IL-18 levels and inflammasome activation. Here, IL18 is linked to hyperinsulinemic hypoglycemia, familial, 4.